Autoimmune Diseases  >>  Simponi (golimumab)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
GO-NICE, NCT01313858: A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)

Completed
N/A
1613
Europe
Simponi®, Golimumab, Methotrexate
Merck Sharp & Dohme LLC
Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing
09/15
09/15
NCT01692457: A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Withdrawn
N/A
0
RoW
No intervention, SIMPONI
Janssen Pharmaceutica
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
07/16
07/16
GO-IV, NCT02390700: Observational Study of Golimumab Intravenous Infusion

Terminated
N/A
78
Canada
Golimumab Intravenous, SIMPONI
Janssen Inc.
Rheumatoid Arthritis
10/16
10/16
Go-Compl-Ar, NCT02414984: Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab

Terminated
N/A
37
RoW
Golimumab, CNTO148
Janssen-Cilag, S.A.
Rheumatoid Arthritis
11/16
11/16

Download Options